Evidence map›Paper›PMID 38326274›Full record

Observational studyVirulence2024

Safety and immunogenicity of CoronaVac in healthy adults: A prospective observational multicenter real-world study in Henan Province, China.

Benchen Rao, Ling Wang, Mengzhao Yang, Hong Luo, Junyi Sun, Shanshuo Liu, Haiyu Wang, Xuemei Wang, Lei Li, Chengyu Yuan and 2 more

Open access · goldAbstract readObservational StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Virulence, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Benchen RaoDepartment of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Ling WangDepartment of Laboratory Medicine, Henan Provincial Chest Hospital, Zhengzhou, China.
Mengzhao YangDepartment of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Hong LuoDepartment of Laboratory Medicine, Guangshan County People's Hospital, Xinyang, Henan, China.
Junyi SunDepartment of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Shanshuo LiuDepartment of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Haiyu WangDepartment of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Xuemei WangDepartment of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Lei LiDepartment of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Chengyu YuanDepartment of Laboratory Medicine, Guangshan County People's Hospital, Xinyang, Henan, China.
Zujiang YuDepartment of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Zhigang RenDepartment of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.ORCID 0000-0003-0798-3444
First Affiliated Hospital of Zhengzhou University · CNPeople’s Hospital of Wenshan Prefecture · CNHenan Provincial Chest Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vaccination has emerged as the primar approach for managing the COVID-19 pandemic. Despite certain clinical trials reporting the safety and immunogenicity of CoronaVac, additional multicenter real-world studies are still necessary. In this study, we recruited 506 healthy volunteers who were not infected with COVID-19 or vaccinated. Each participant provided peripheral blood samples three times: prior to the first dose of vaccine, prior to the second dose, and 8 weeks following the second dose. Ultimately, 388 participants completed the entire follow-up process. No serious adverse events were observed among any of the participants. Within 1 week of vaccination, 13.4% of participants experienced systemic adverse reactions, with fatigue (5.93%) and dizziness (3.35%) being the most frequent. Although some clinical indicators, including creatinine, significantly changed after vaccination (

Indexed as

COVID-19COVID-19 VaccinesPandemicsVaccines, InactivatedAdultAntibodies, NeutralizingChinaHumansImmunogenicity, VaccineAntibodies, NeutralizingCOVID-19 Vaccinessinovac COVID-19 vaccineVaccines, InactivatedCoronaVacimmunogenicityneutralizing antibodiesprediction modelsafety

Identifiers

PMID38326274
PMCPMC10854291
OpenAlexW4391649390

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.